A Phase I, Open Label, Multi-center, Parallel Cohort, Single Dose Study to Evaluate the Pharmacokinetics of LEE011 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Ribociclib (Primary)
- Indications Liver disorders
- Focus Pharmacokinetics
- Sponsors Novartis
- 13 Feb 2017 Status changed from recruiting to completed.
- 11 Sep 2016 Planned number of patients changed from 36 to 30.
- 11 Sep 2016 Planned End Date changed from 1 Nov 2016 to 1 Jan 2017.